Abstract
Niacin-ligated platinum(iv)-ruthenium(ii) chimeric complexes (PtRu 1-4) have been synthesized and evaluated for their antitumor performance. Using the optimal complex, PtRu-1, we show that this water-soluble chimeric prodrug not only potently inhibits the metastasis and proliferation of tumor cells but also has an unexpectedly higher safety margin in animals compared with the traditionally-used, clinically approved drug cisplatin.
MeSH terms
-
Animals
-
Antineoplastic Agents / chemical synthesis
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / pharmacology*
-
Body Weight / drug effects
-
Cell Line, Tumor
-
Cell Proliferation / drug effects
-
Cisplatin / chemistry
-
Cisplatin / pharmacology
-
Coordination Complexes / chemical synthesis
-
Coordination Complexes / chemistry
-
Coordination Complexes / pharmacology*
-
Dose-Response Relationship, Drug
-
Drug Screening Assays, Antitumor
-
Female
-
Humans
-
Mice
-
Mice, Inbred BALB C
-
Mice, Inbred ICR
-
Mice, Nude
-
Molecular Structure
-
Neoplasms, Experimental / drug therapy
-
Neoplasms, Experimental / pathology
-
Niacin / chemistry
-
Niacin / pharmacology*
-
Platinum / chemistry
-
Platinum / pharmacology*
-
Ruthenium / chemistry
-
Ruthenium / pharmacology*
-
Structure-Activity Relationship
Substances
-
Antineoplastic Agents
-
Coordination Complexes
-
Niacin
-
Platinum
-
Ruthenium
-
Cisplatin